Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eagle Pharmaceuticals stock

Own Eagle Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Eagle Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Eagle Pharmaceuticals shares (EGRX) are listed on the NASDAQ and all prices are listed in US Dollars. Eagle Pharmaceuticals employs 108 staff and has a trailing 12-month revenue of around USD$177.4 million.

How to buy shares in Eagle Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Eagle Pharmaceuticals. Find the stock by name or ticker symbol: EGRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eagle Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Eagle Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Eagle Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Eagle Pharmaceuticals share price

Use our graph to track the performance of EGRX stocks over time.

Eagle Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
52-week range USD$33.8 - USD$64.94
50-day moving average USD$41.2466
200-day moving average USD$46.6341
Wall St. target price USD$49.33
PE ratio 257.7222
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.177

Buy Eagle Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Eagle Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Eagle Pharmaceuticals under- or over-valued?

Valuing Eagle Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eagle Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eagle Pharmaceuticals's P/E ratio

Eagle Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 258x. In other words, Eagle Pharmaceuticals shares trade at around 258x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eagle Pharmaceuticals's PEG ratio

Eagle Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.91. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eagle Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eagle Pharmaceuticals's EBITDA

Eagle Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$11.7 million.

The EBITDA is a measure of a Eagle Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Eagle Pharmaceuticals financials

Revenue TTM USD$177.4 million
Operating margin TTM 4.6%
Gross profit TTM USD$135 million
Return on assets TTM 1.97%
Return on equity TTM -2.53%
Profit margin -2.54%
Book value $13.523
Market capitalisation USD$596.8 million

TTM: trailing 12 months

Shorting Eagle Pharmaceuticals shares

There are currently 2.3 million Eagle Pharmaceuticals shares held short by investors – that's known as Eagle Pharmaceuticals's "short interest". This figure is 27.4% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Eagle Pharmaceuticals shares can be evaluated.

Eagle Pharmaceuticals's "short interest ratio" (SIR)

Eagle Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Eagle Pharmaceuticals shares currently shorted divided by the average quantity of Eagle Pharmaceuticals shares traded daily (recently around 220674.29951691). Eagle Pharmaceuticals's SIR currently stands at 10.35. In other words for every 100,000 Eagle Pharmaceuticals shares traded daily on the market, roughly 10350 shares are currently held short.

However Eagle Pharmaceuticals's short interest can also be evaluated against the total number of Eagle Pharmaceuticals shares, or, against the total number of tradable Eagle Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eagle Pharmaceuticals's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Eagle Pharmaceuticals shares in existence, roughly 180 shares are currently held short) or 0.2873% of the tradable shares (for every 100,000 tradable Eagle Pharmaceuticals shares, roughly 287 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Eagle Pharmaceuticals.

Find out more about how you can short Eagle Pharmaceuticals stock.

Eagle Pharmaceuticals share dividends

We're not expecting Eagle Pharmaceuticals to pay a dividend over the next 12 months.

Eagle Pharmaceuticals share price volatility

Over the last 12 months, Eagle Pharmaceuticals's shares have ranged in value from as little as $33.8 up to $64.94. A popular way to gauge a stock's volatility is its "beta".

EGRX.US volatility(beta: 0.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eagle Pharmaceuticals's is 0.6922. This would suggest that Eagle Pharmaceuticals's shares are less volatile than average (for this exchange).

Eagle Pharmaceuticals overview

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site